tbuckley/cabot-search huggingface dataset:
TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study
Authors: Y. Nakamura, W. Okamoto, T. Kato, H. Hasegawa, K. Kato, S. Iwasa, T. Esaki, Y. Komatsu, T. Masuishi, T. Nishina, S. Nomura, M. Fukui, S. Matsuda, A. Sato, S. Fujii, J.I. Odegaard, S. Olsen, T. Yoshino
Journal: Annals of Oncology (2019)
Clinical mucositis and intestinal permeability abnormalities in metastatic colorectal cancer patients treated with irinotecan and 5-fluoruracil.
Authors: Markus Gifoni, Roberto Cesar Lima, Aldo Angelo Moreira Lima, Adriana Facanha, Rodrigo Barbosa Callado, Carolina Azevedo, Ronaldo De Albuquerque Ribeiro
Journal: Journal of Clinical Oncology (2012)

e14183 Background: The comprehension of the mechanisms involved in the adverse events of the cytotoxic drugs available to treat metastatic colorctal cancer (CRC) is necessary to improve their efficacy and safety. The irinotecan, fluoruracil and folinic acid (IFL) bolus regimen have as its major toxicity issue the complex and multi-mediated gastrointestinal mucositis. Nevertheless, it is difficult to obtain a reliable measurement of the intestinal abnormalities and functional consequences caused by intestinal mucositis, as almost all the clinical data available are reported on a patient symptoms-based scale analysis. Methods: With the lactulose/ mannitol permeability test as the experimental platform, we did a prospective case control study with 25 metastatic CRC patients treated with first line IFL. The primary end point was to compare (Wilcoxon test) the lactulose/ mannitol permeability test before the treatment and the same patients tests at the 15th and 29th day of the first IFL cycle. Blood samples of the same individuals were obtained before the treatment and at 15th day of their first IFL cycle to compare the ELISA serum levels of potentially involved cytokines (TNFα, IL-1β, IL-6, IL-18, IL-18bp e IL-33) (paired t-test). Results: In contrast with the pretreatment controls, the lactulose/ mannitol ratio was significantly (p&lt;0,05) increased at the D15 and D29 in patients taking the first IFL cycle. The mannitol excretion rate was also decreased (p&lt;0,05) at the 29th day. This abnormalities also reserve significant (p&lt;0,05 – Spearman coeficient) correlation with the diarrhea and abdominal pain symptoms (NCI-CTC version 4.0) scale reported by the patients. Otherwise, it has not been possible to demonstrate serum levels differences of the addressed cytokines before and after the treatment. Conclusions: The lactulose/ mannitol permeability test is an objective and reliable tool to measure intestinal permeability abnormalities secondary to gastrointestinal mucositis caused by IFL to metastatic CRC patients.This non-invasive test could bring more objetctive measurement of the functional consequences of this limiting toxicity.
Abstract 11427: Ethnic Differences in Factors Precipitating Hospital Admissions for Heart Failure in Middle-Eastern Arabs and South Asians: Insights From the Gulf CARE Registry
Authors: Amar M Salam, Kadhim Sulaiman, Robert O Bonow, Jassim Al-Suwaidi, Khalid AlHabib, Wael Almahmeed, Alawi Alsheikh-Ali, Prashanth Panduranga, Husam AlFaleh, Abdelfatah Elasfar, Ahmed Al-Motarreb, Nooshin Bazargani, Mustafa Ridha, Bassam Bulbanat, Mohammed Al-Jarallah, Haitham Amin, Nidal Asaad, Awad Al-Qahtani, Rajvir Singh, Magdi Yacoub
Journal: Circulation (2014)

OBJECTIVES: No previous studies have specifically examined the effects of ethnicity on factors precipitating hospital admissions for heart Failure (HF). The aim of the current study was to identify factors precipitating HF hospitalizations peculiar to Middle-Eastern Arab and South Asian ethnicities using a large multinational multicenter Middle-Eastern HF registry in which these two ethnicities are most prevalent. METHODS: From February 2012 to November 2013, consecutive patients hospitalized with HF were enrolled from 47 hospitals in 7 Middle East countries. Identifiable factors contributing to HF hospitalization were pre-specified and captured at admission. Patients were divided into 2 groups according to ethnicity, Arabs and South Asians (referred to as Asians) and the 2 groups were compared. RESULTS: During the study period 5005 patients with HF were enrolled of whom 4989 patients were from the 2 ethnicities under study; 4516 Arabs (90.5%) and 473(9.5%) Asians with the mean age of 60 years for Arabs and 55 years for Asians. The mean left ventricular ejection fraction was 37 % for Arabs compared to 33.8 % for Asians, P=0.001. Among the precipitating factors studied, nonadherence to medications and infections were significantly more prevalent in Arabs compared to Asians (19.9% vs. 13.5% and 15.3% vs.8.5%, both P=0.001) whereas myocardial ischemia and uncontrolled hypertension were significantly more prevalent in Asians (40.4% vs. 25.9% and 11.6% vs.7.8%, both P=0.001). In both groups, however, myocardial ischemia and nonadherence to medications were the commonest two factors precipitating hospital admissions for HF (table). CONCLUSIONS: Our study identifies for the first time important ethnic related differences in precipitating factors for HF hospitalizations among Arabs and Asians living in the Middle-East. The current study underscores the need to consider ethnicity in studies of HF hospitalizations and HF outcomes.
Disparities starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase III OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274)
Authors: L. Mileshkin, E. Barnes, K.N. Moore, V. Gebski, M. King, K. Narayan, I.K. Kolodziej, K. Sjoquist, A. Fyles, W. Small, D. Gaffney, M. Quinn, J. Andrews, S. Thompson, W. Huh, M. Carlson, P.A. Disilvestro, D. Rischin, M.R. Stockler, B.J. Monk
Journal: Annals of Oncology (2019)
Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
Authors: S.Y.F. Fu, A. Murtha, C. Herberts, S. Yip, A. Angeles, S.J. Hotte, A. Alshangiti, B. Tran, S. Taavitsainen, M. Annala, F. Saad, N.N. Iqbal, A.W. Wyatt, K.N. Chi
Journal: Annals of Oncology (2019)
Aligning Care With Patient Values and Priorities
Authors: Ian G. Hargraves, Victor M. Montori
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Spanish registry of thoracic tumors (TTR): Interim analyses of comorbidities, risk associations, personal and family history of cancer
Authors: R. Lopez Castro, P. Lianes, E. Nogueron Martnez, P. Diz Tain, J. Calzas, O.J. Juan Vidal, M. Sereno Moyano, M.A. Muñoz, M. Guillot Morales, L. Capdevila Riera, J.A. Campillo Fuentes, J. Valdivia-Bautista, M. Cobo Dols, A. Paredes Lario, X. Mielgo Rubio, M. Majem Tarruella, M. Martínez, J.M. Sanchez Torres, B. Rubio-Viqueira, M. Provencio
Journal: Annals of Oncology (2019)
Abstract 15915: Integrated Plaque and Plasma Proteo-Lipidomics Reveal Novel Signatures of Coronary Atherosclerotic Plaque Disruption
Authors: Regent Lee, David Adlam, Roman Fischer, Katalin Di Gleria, Alessandro Valli, Philip Charles, Joanna McGouran, Neil Ruparelia, Sam Dawkins, Rajesh K Kharbanda, Robin P Choudhury, Charalambos Antoniades, Benedikt M Kessler, Keith M Channon
Journal: Circulation (2013)

Background: Clinical consequences of atherosclerotic plaque rupture vary between asymptomatic to acute arterial thrombosis, yet the mechanisms underpinning such differential biological response rem...
Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders
Authors: V. Conteduca, O. Caffo, E. Scarpi, P. Sepe, L. Galli, L. Fratino, F. Maines, V.E. Chiuri, M. Santoni, E. Zanardi, F. Massari, I. Toma, G. Schepisi, A. Sbrana, S. Kinspergher, M.C. Cursano, C. Modonesi, D. Santini, G. Procopio, U.F.F. De Giorgi
Journal: Annals of Oncology (2019)
Muscarinic receptor M3 contributes to vascular and neural growth factor up‐regulation in severe asthma
Authors: Anna Folino, Vitina Carriero, Michela Bullone, Francesca Bertolini, Antonino Di Stefano, Mirella Profita, Bruno Balbi, Michael Pieper, Fabio L. M. Ricciardolo
Journal: Allergy (2019)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent
Authors: K. Ruggero, A. Martinez, X. Chen, R El Bizri, S. Farran, L. Palomero, J.M. Piulats, A. Villanueva, M.A. Pujana, A. Aytes
Journal: Annals of Oncology (2019)
THU-227-NTCP S267F variant associates with decreased susceptibility to HBV infection and decelerated progression of related liver diseases
Authors: Thanh Binh Mai, Xuan Hoan Nghiem, Tong Hoang, Tien Sy Bui, Tat Trung Ngo, C.-Thomas Bock, Linh Toan Nguyen, Huu Song Le, Hong Bang Mai, Christian G. Meyer, Thirumalaisamy P. Velavan
Journal: Journal of Hepatology (2019)
154 compared to 54 mmol per liter of sodium in intravenous maintenance fluid therapy for adult patients undergoing major thoracic surgery (TOPMAST): a single-center randomized controlled double-blind trial
Authors: Niels Van Regenmortel, Steven Hendrickx, Ella Roelant, Ingrid Baar, Karolien Dams, Karen Van Vlimmeren, Bart Embrecht, Anouk Wittock, Jeroen M. Hendriks, Patrick Lauwers, Paul E. Van Schil, Amaryllis H. Van Craenenbroeck, Walter Verbrugghe, Manu L. N. G. Malbrain, Tim Van den Wyngaert, Philippe G. Jorens
Journal: Intensive Care Medicine (2019)

To determine the effects of the sodium content of maintenance fluid therapy on cumulative fluid balance and electrolyte disorders. We performed a randomized controlled trial of adults undergoing major thoracic surgery, randomly assigned (1:1) to receive maintenance fluids containing 154 mmol/L (Na154) or 54 mmol/L (Na54) of sodium from the start of surgery until their discharge from the ICU, the occurrence of a serious adverse event or the third postoperative day at the latest. Investigators, caregivers and patients were blinded to the treatment. Primary outcome was cumulative fluid balance. Electrolyte disturbances were assessed as secondary endpoints, different adverse events and physiological markers as safety and exploratory endpoints. We randomly assigned 70 patients; primary outcome data were available for 33 and 34 patients in the Na54 and Na154 treatment arms, respectively. Estimated cumulative fluid balance at 72 h was 1369 mL (95% CI 601–2137) more positive in the Na154 arm (p < 0.001), despite comparable non-study fluid sources. Hyponatremia < 135 mmol/L was encountered in four patients (11.8%) under Na54 compared to none under Na154 (p = 0.04), but there was no significantly more hyponatremia < 130 mmol/L (1 versus 0; p = 0.31). There was more hyperchloremia > 109 mmol/L under Na154 (24/35 patients, 68.6%) than under Na54 (4/34 patients, 11.8%) (p < 0.001). The treating clinicians discontinued the study due to clinical or radiographic fluid overload in six patients receiving Na154 compared to one patient under Na54 (excess risk 14.2%; 95% CI − 0.2–30.4%, p = 0.05). In adult surgical patients, sodium-rich maintenance solutions were associated with a more positive cumulative fluid balance and hyperchloremia; hypotonic fluids were associated with mild and asymptomatic hyponatremia.
Novel blood based circulating tumour cell biomarker for breast cancer detection
Authors: C.-Y. Liu, Y.-F. Tsai, F.-M. Lin, J.-C. Wu, Y.-S. Lin, T.-C. Chao, K.-L. King, P.-J. Lien, J. Wang, Y.-H. Lin, Y.-C. Lai, H.B. Hsieh, A. Saklecha, J.-M. Lai, S.-E. Chang, M. Javey, D. Watson, R. Mei, L.-M. Tseng
Journal: Annals of Oncology (2019)
Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
Authors: M. De Laurentiis, A. Ring, M. Campone, T. Bachelot, W. Jacot, P. Marchetti, C. Timcheva, B. De Valk, A. Gombos, L. Menon-Singh, J. Wu, K. Zhou, P. Neven
Journal: Annals of Oncology (2019)
Is MGMT methylation a new therapeutic target for biliary tract cancer?
Authors: M. Niger, F. Morano, S. Manglaviti, F. Nichetti, E. Tamborini, F. Perrone, M. Marcuzzo, G. Peverelli, M. Brambilla, F. Pagani, M. Torchio, A. Ottini, M. Antista, F. Pietrantonio, S. Pusceddu, G. Pruneri, M. Di Bartolomeo, F.G.M. De Braud
Journal: Annals of Oncology (2019)
Towards a screening test for cancer by circulating DNA analysis
Authors: R. Tanos, A. Otandault, C. Mollevi, A. Bauer, G. Tousch, L. Picque Lasorsa, S. El Messaoudi, J. Colinge, P.-E. Colombo, W. Jacot, T. Mazard, J.M. Sayagués, B. Gillet, D. Pezet, M. Ychou, A.R. Thierry
Journal: Annals of Oncology (2019)
Pivotal role of PDK1 in megakaryocyte cytoskeletal dynamics and polarization during platelet biogenesis
Authors: Sascha Geue, Katja Aurbach, Mailin-Christin Manke, Georgi Manukjan, Patrick Münzer, David Stegner, Caroline Brähler, Britta Walker-Allgaier, Melanie Märklin, Carla E. Borst, Leticia Quintanilla-Fend, Dominik Rath, Tobias Geisler, Helmut R. Salih, Peter Seizer, Florian Lang, Bernhard Nieswandt, Meinrad Gawaz, Harald Schulze, Irina Pleines, Oliver Borst
Journal: Blood (2019)
Extracorporeal liver support in patients with liver failure: a systematic review and meta-analysis of randomized trials
Authors: Fayez Alshamsi, Khalil Alshammari, Emilie Belley-Cote, Joanna Dionne, Talal Albrahim, Budoor Albudoor, Mona Ismail, Bandar Al-judaibi, Bandar Baw, Ram M. Subramanian, Randolph Steadman, Dragos Galusca, David T. Huang, Rahul Nanchal, Mustafa Al Quraini, Yuhong Yuan, Waleed Alhazzani
Journal: Intensive Care Medicine (2019)
SEGMENTAL ANALYSIS OF T1-201 STRESS MYOCARDIAL SCINTIGRAPHY: RESULTS FROM A BILATERAL ROTATING SLANTHOLE SPECT IMAGING SYSTEM.
Authors: R. Blumhardt, F. L. Weiland, J. C. Lasher, M. R. Starling
Journal: Clinical Nuclear Medicine (1983)

University of Texas Health Science Center at San Antonio, Texas and Wilford Hall Air Force Medical Center, San Antonio, Texas
SMARCA4 deficient non-small cell lung cancer (NSCLC): A comprehensive genomic profiling (CGP) study
Authors: S.L. Graziano, D. Lin, J.A. Elvin, J.-A. Vergilio, J.K. Killian, N. Ngo, S. Ramkissoon, E. Severson, A. Hemmerich, D. Duncan, C. Edgerly, S.M. Ali, A.B. Schrock, J. Chung, E.S. Sokol, P. Reddy, K. McGregor, V.A. Miller, B.M. Alexander, J.S. Ross
Journal: Annals of Oncology (2019)
Effects of delayed initiation of adjuvant trastuzumab for non-metastatic, HER2 positive breast cancer in a limited resources setting: ML25232 study final results
Authors: S. Beslija, T. Ceric, B. Hasanbegovic, F. Skenderi, J. Alidžanović, D. Kopric, I. Marjanović, A. Mekic-Abazovic, I.S. Sisic, M. Hammami, A. Pasic, A. Rasic, E. Kapisazović
Journal: Annals of Oncology (2019)
The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC)
Authors: T. Kawakami, T. Masuishi, Y. Kawamoto, H. Go, H. Shirasu, K. Kato, R. Kumanishi, K. Sawada, K. Yamamoto, S. Yuki, Y. Komatsu, H. Yasui, K. Muro, T. Yamanaka, K. Yamazaki
Journal: Annals of Oncology (2019)
Abstract 3000: MicroRNA-21 as a biomarker for benefit from adjuvant therapy in resectable pancreatic adenocarcinoma
Authors: Johannes Voortman, Jin-Hyeok Hwang, Elisa Giovannetti, Seth M. Steinberg, Yong-Tae Kim, Niccola Funel, Joo Kyung Park, Min A. Kim, Gyeong Hoon Kang, Sun-Whe Kim, Marco Del Chiaro, Godefridus J. Peters, Giuseppe Giaccone
Journal: Cancer Research (2010)

Abstract Many pancreatic adenocarcinoma patients who undergo surgical resection receive adjuvant chemotherapy and/or combined modality treatment. However, only a subset of patients benefit from additional therapy. The aim of this study was to evaluate the expression of several potential markers of treatment outcome. Resected tumors of a cohort of 82 pancreatic adenocarcinoma patients from Korea were analyzed for protein expression of 20 markers by immunohistochemistry and expression of 7 microRNAs using quantitative real-time PCR. A second validation cohort of 45 resected Italian patients was analyzed for microRNA-21 (miR-21) expression. Korean and Italian cases consisted of FFPE and frozen specimens, respectively. Univariate and multivariate analyses were used to compare biological parameters and survival endpoints. In the Korean cohort, Cox proportional hazards model analysis in the subgroup of patients treated with adjuvant therapy (N=52) showed that lower than median miR-21 expression was associated with a significantly lower HR for death (0.316; 95% CI: 0.166-0.600; p-value: 0.0004) and recurrence (0.521; 95% CI: 0.280-0.967; p-value: 0.04). Expression status of miR-21 was the single most predictive biomarker for treatment outcome from all factors evaluated. No significant association of miR-21 expression status with prognosis was detected in patients not treated with adjuvant therapy. In the independent cohort of 45 Italian cases, all treated with adjuvant therapy, lower than median miR-21 expression was also significantly correlated with longer overall and disease-free survival confirming its predictive value. Concluding, low miR-21 expression was associated with benefit from adjuvant treatment in two independent cohorts of pancreatic cancer cases, using both FFPE and frozen tumor specimens. These data provide evidence that miR-21 expression may allow stratification of pancreatic cancer patients for adjuvant treatment. This is the first strong predictive marker for adjuvant therapy in radically resected pancreatic cancer and further prospective studies are warranted. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3000.
Polyunsaturated Fatty Acids from Astrocytes Activate PPARγ Signaling in Cancer Cells to Promote Brain Metastasis
Authors: Yongkang Zou, Andrea Watters, Nan Cheng, Caroline E. Perry, Ke Xu, Gretchen M. Alicea, Joshua L.D. Parris, Ezra Baraban, Pulak Ray, Anupma Nayak, Xiaowei Xu, Meenhard Herlyn, Maureen E. Murphy, Ashani T. Weeraratna, Zachary T. Schug, Qing Chen
Journal: Cancer Discovery (2019)

Abstract Brain metastasis, the most lethal form of melanoma and carcinoma, is the consequence of favorable interactions between the invading cancer cells and the brain cells. Peroxisome proliferator–activated receptor γ (PPARγ) has ambiguous functions in cancer development, and its relevance in advanced brain metastasis remains unclear. Here, we demonstrate that astrocytes, the unique brain glial cells, activate PPARγ in brain metastatic cancer cells. PPARγ activation enhances cell proliferation and metastatic outgrowth in the brain. Mechanistically, astrocytes have a high content of polyunsaturated fatty acids that act as “donors” of PPARγ activators to the invading cancer cells. In clinical samples, PPARγ signaling is significantly higher in brain metastatic lesions. Notably, systemic administration of PPARγ antagonists significantly reduces brain metastatic burden in vivo. Our study clarifies a prometastatic role for PPARγ signaling in cancer metastasis in the lipid-rich brain microenvironment and argues for the use of PPARγ blockade to treat brain metastasis. Significance: Brain-tropic cancer cells take advantage of the lipid-rich brain microenvironment to facilitate their proliferation by activating PPARγ signaling. This protumor effect of PPARγ in advanced brain metastases is in contrast to its antitumor function in carcinogenesis and early metastatic steps, indicating that PPARγ has diverse functions at different stages of cancer development. This article is highlighted in the In This Issue feature, p. 1631
A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumour activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib)
Authors: L. Si, L. Mao, L. Zhou, C. Li, X. Wang, C. Cui, X. Sheng, Z. Chi, B. Lian, B. Tang, X. Yan, S. Li, X. Bai, J. Dai, Y. Kong, L. Lin, J. Zhang, Z. Wu, A. Hui, J. Guo
Journal: Annals of Oncology (2019)
Systemic therapy in second-line metastatic triple negative breast cancer (mTNBC): A systematic literature review (SLR) and meta-analysis (MA) of efficacy
Authors: P.A. Kaufman, C.S. Kwon, J. Feliciano, T. Westley, A. Forsythe, P. Garfin, L. Brown
Journal: Annals of Oncology (2019)
Clinical outcomes of immune checkpoint inhibitors in older and younger patients with advanced solid tumours in a real-life setting
Authors: P. Corbaux, D. Maillet, A. Boespflug, M Locatelli Sanchez, M Perier Muzet, M. Duruisseaux, L Kiakouama Maleka, S. Dalle, C. Falandry, J. Peron
Journal: Annals of Oncology (2019)
Influence of cow’s milk on the absorption and exposure of erlotinib in NSCLC patients
Authors: G.D.M. Veerman, K G A M Hussaarts, R. Peric, E. Oomen-de Hoop, K. Landa, C.H. Van Der Leest, S.D. Broerse, H.B. Rutten, M.S. Paats, T. van Gelder, S.L. Koolen, J.G. Aerts, R.W. van Leeuwen, R.H. Mathijssen
Journal: Annals of Oncology (2019)
Long-term effects of rent supplements and mental health support services on housing and health outcomes of homeless adults with mental illness: extension study of the At Home/Chez Soi randomised controlled trial
Authors: Vicky Stergiopoulos, Cilia Mejia-Lancheros, Rosane Nisenbaum, Ri Wang, James Lachaud, Patricia O'Campo, Stephen W Hwang
Journal: The Lancet Psychiatry (2019)
Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real-world data from a European Cohort with focus on subgroups of interest
Authors: G. Mountzios, D. Signorelli, J Rey Cobo, M. Banini, P. Economopoulou, G Lo Russo, P.T. Baxevanos, F. Roila, A. de Toma, G. Banna, A. Christopoulou, B. Jimenez, H. Linardou, A. Calles, D. Galetta, A. Addeo, A. Camerini, P.A. Kosmidis, M.C. Garassino, G. Metro
Journal: Annals of Oncology (2019)
Kinetics of Molecular Response among Newly Diagnosed Patients with PML-RARα+ Acute Promyelocytic Leukemia Treated with Arsenic Trioxide.
Authors: Ezhilarasi Chendamarai, Kavitha M. Lakshmi, Auro Viswabandya, Alok Srivastava, Mammen Chandy, Vikram Mathews
Journal: Blood (2007)
Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Authors: S. Dalle, L. Mortier, P. Corrie, M. Lotem, R. Board, A.M. Arance, F. Meiss, P. Terheyden, R. Gutzmer, J. Brokaw, T.K. Le, S.D. Mathias, J. Scotto, J. Lord-Bessen, A. Moshyk, S. Kotapati, M.R. Middleton
Journal: Annals of Oncology (2019)
Results of the 3rd interim analysis of C-Patrol: A non-interventional study on olaparib in German routine clinical practice
Authors: J. Sehouli, F. Hilpert, M.K. Welslau, J.P. Grabowski, J. Seitz, A. El-Balat, A. Hartkopf, R. Glowik, F. Marmé
Journal: Annals of Oncology (2019)